Podcast: USP's Matthew van Hook on Biosimilars - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Podcast: USP's Matthew van Hook on Biosimilars


USP's Matthew van Hook on Biosimilars Standards

Assistant General Counsel of the US Pharmacopeia, Matthew van Hook discusses what companies need to plan for with regard to biosimilar applications, exclusivity, and more. Recorded LIVE at the USP 2011 Science and Standards Symposium, October 2011.
Interviewed by Angie Drakulich, senior managing editor.

Related podcast with Gillian Woollet

Related podcast with Tina Morris

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes

Click here